Status epilepticus: Evaluation, Prognose und Klassifikation von Roy Strowd, MD

video locked

Über den Vortrag

Der Vortrag „Status epilepticus: Evaluation, Prognose und Klassifikation“ von Roy Strowd, MD ist Bestandteil des Kurses „Anfälle und Epilepsie“.


Quiz zum Vortrag

  1. Medication compliance is critical in preventing breakthrough seizures.
  2. Fevers are the most common cause of breakthrough seizures.
  3. A head CT is necessary after every breakthrough seizure to look for a potential nidus.
  4. Routine labs should be avoided following a breakthrough seizure.
  5. Changing the patient’s medication regimen is the first step of treatment.
  1. A prolonged or recurrent seizure lasting longer than 30 minutes.
  2. Any convulsive episode that does not respond to treatment.
  3. Any seizure that does not resolve spontaneously in under 5 minutes.
  4. A prolonged seizure lasting more than 1 hour.
  5. Any seizure that causes lasting brain damage or death.
  1. It usually presents as a febrile illness in young children.
  2. It accounts for 20% of all hospital admissions.
  3. Most patients with epilepsy will have at least one episode of SE.
  4. SE is more common in children over the age of 8 years.
  5. Most cases of SE present without convulsions.
  1. Mortality is significantly higher if the episode lasts longer than 1 hour.
  2. It is a medical emergency with a mortality rate higher than 50% in children.
  3. The mortality in adults is lower than that in children.
  4. The underlying etiology does not impact mortality.
  5. Advanced age is protective in terms of mortality.
  1. Refractory SE is a term used when a patient does not respond to antiepileptic drugs.
  2. Convulsive SE is harder to treat than non-convulsive SE.
  3. Non-convulsive SE is usually easy to recognize.
  4. Patients with super-refractory SE are treated effectively by a medically induced coma.
  5. Patients with refractory or super-refractory SE generally become more responsive to treatment with each episode.

Dozent des Vortrages Status epilepticus: Evaluation, Prognose und Klassifikation

 Roy Strowd, MD

Roy Strowd, MD

Dr. Roy Strowd is the Assistant Dean of Undergraduate Medical Education at the Wake Forest Baptist Medical Center, in North Carolina, USA.
He obtained his MD from Wake Forest School of Medicine in 2009, and his MEd from Johns Hopkins University in 2021. Currently, he co-directs the Neurofibromatosis and Tuberous Sclerosis Clinics at Wake Forest Baptist Medical Center, and is a researcher for the Adult Brain Tumor Consortium (ABTC) and Alliance for Clinical Trials in Neuro-Oncology.
Due to his achievements, he earned the M. Brownell Anderson Award from the Association of American Medical Colleges.
Within Lecturio, Dr. Strowd teaches courses on Clinical Neurology.


Kundenrezensionen

(1)
5,0 von 5 Sternen
5 Sterne
5
4 Sterne
0
3 Sterne
0
2 Sterne
0
1  Stern
0